HC Wainwright Has Pessimistic View of Arvinas Q1 Earnings

Arvinas, Inc. (NASDAQ:ARVN) – HC Wainwright dropped their Q1 2026 earnings estimates for shares of Arvinas in a report released on Wednesday, February 25th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.89) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas’ Q2 2026 earnings at ($0.86) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.50) EPS, FY2027 earnings at ($3.14) EPS, FY2028 earnings at $3.09 EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $5.60 EPS.

Several other research firms have also recently commented on ARVN. Wedbush lifted their price target on Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday. Barclays raised their target price on shares of Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 price target (up from $16.00) on shares of Arvinas in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Finally, Stephens lifted their price target on shares of Arvinas from $14.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, November 10th. Ten analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Arvinas has an average rating of “Hold” and a consensus price target of $13.47.

Arvinas Trading Down 0.8%

NASDAQ ARVN opened at $13.27 on Friday. The business’s 50-day moving average price is $12.48 and its 200 day moving average price is $10.60. Arvinas has a twelve month low of $5.90 and a twelve month high of $18.93. The company has a market capitalization of $848.75 million, a PE ratio of -10.37 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The business had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.Arvinas’s revenue for the quarter was down 84.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.63) EPS.

Insider Activity

In other news, CFO Andrew Saik sold 5,134 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $11.89, for a total transaction of $61,043.26. Following the completion of the sale, the chief financial officer directly owned 159,267 shares in the company, valued at $1,893,684.63. This trade represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Randy Teel sold 4,786 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total value of $58,197.76. Following the completion of the transaction, the chief executive officer owned 149,696 shares in the company, valued at approximately $1,820,303.36. This trade represents a 3.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 22,132 shares of company stock worth $264,741. 4.73% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arvinas

Several institutional investors and hedge funds have recently made changes to their positions in ARVN. Armistice Capital LLC raised its holdings in Arvinas by 50.0% in the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after acquiring an additional 600,000 shares in the last quarter. TCG Crossover Management LLC bought a new stake in shares of Arvinas in the 3rd quarter worth about $13,780,000. Geode Capital Management LLC raised its stake in shares of Arvinas by 3.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,585,092 shares of the company’s stock valued at $11,668,000 after purchasing an additional 48,296 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Arvinas by 154.8% during the third quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after purchasing an additional 903,337 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in Arvinas by 791.1% in the second quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock worth $10,498,000 after purchasing an additional 1,267,593 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $20, signaling meaningful upside versus current levels. Read More.
• Positive Sentiment: HC Wainwright raised longer‑range earnings projections for FY2028–FY2030 (FY2028 to $3.09, FY2029 to $1.76, FY2030 to $5.60), implying stronger late‑cycle profitability if clinical/program milestones are met. Read More.
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Ikarian among buyers), which can support liquidity and indicate some investor confidence in the pipeline. Read More.
• Neutral Sentiment: Street consensus remains mixed (MarketBeat shows a “Hold” consensus with a $13.47 average target), so analyst moves are not uniform — upgrades from some firms may not sway broader sentiment. Read More.
• Neutral Sentiment: Reported short‑interest figures in recent updates appear to be erroneous (showing 0 shares/NaN), so short‑interest/read‑through risk is unclear until corrected data is published. (data report)
• Negative Sentiment: HC Wainwright sharply cut near‑term estimates (Q1–Q4 2026 and FY2026/FY2027 EPS downgraded), lowering expected profitability this year and next — a near‑term negative catalyst for the stock. Read More.
• Negative Sentiment: Q4 2025 results were a clear negative: EPS and revenue missed materially (reported -$1.10 EPS vs. -$0.55 expected; revenue $9.5M vs. $37.3M expected), which is the primary driver pressuring the share price. Read More.
• Negative Sentiment: Insider sales: CEO Randy Teel and CAO David Loomis sold shares on Feb. 23 (modest reductions). Insider selling can be perceived negatively even when routine; filings: Read More., Read More.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.